# 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

> **NCT03110575** · PHASE3 · TERMINATED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 190 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** TNX-102 SL

## Key facts

- **NCT ID:** NCT03110575
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-20
- **Primary completion:** 2018-07-27
- **Final completion:** 2018-07-27
- **Target enrollment:** 190 (ACTUAL)
- **Why stopped:** Stopped early due to inadequate separation on primary efficacy endpoint in the lead-in HONOR study, TNX-CY-P301
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110575, "12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03110575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*